Cancer
01 Jan 2013
Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer
In this Phase IIIb, randomized, double-blind, maintenance study, 300 subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) (Stage IIIB {T4-pleural effusion} and IV) who have SD or objective tumor response immediately following the completion of 4-6 cycles of front line, platinum-based, doublet chemotherapy will be randomized in a…
Children's health
01 Jan 2013
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children and Adolescent Patients with Bipolar I Mania
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of children and adolescent patients with Bipolar I mania. Official Title Conditions Bipolar Disorder Study Type Interventional Study Design Treatment, Placebo Control, Safety/Efficacy Study Further Details Study Start…
Heart
01 Jan 2013
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs
Clinical investigations have demonstrated a link between use of the sulfone cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, and increased risk for atherothrombotic events. This increased risk was not observed for a sulfonamide COX-2 inhibitor (celecoxib), indicating a potential non-enzymatic mechanism for rofexocib. To test this hypothesis, researchers compared the independent effects…
Heart
01 Jan 2013
Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT)
To evaluate the effectiveness of aldosterone antagonist therapy in reducing all cause mortality in patients who have heart failure with preserved systolic function. Official Title Conditions – Cardiovascular Diseases- Heart Diseases- Heart Failure Study Type Interventional Study Design Treatment, Randomized, Double-Blind, Placebo Control Further Details BACKGROUND: Heart failure (HF)…
Neurology
01 Jan 2013
Prevention of cognitive decline in Alzheimer’s disease by ingested interferon alpha
In this phase I-II parallel design, randomized, double-blind clinical trial we will determine if 3,000 or 30,000 units ingested hrIFN-a prevents deterioration of cognitive functioning in patients with dementia of Alzheimer’s type (AD) and whether ingested hrIFN-a treatment decreases acute phase reactants and pro-inflammatory cytokine IL-6 in mild to moderate…
Blood
01 Jan 2013
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard treatment includes…
Lungs
01 Jan 2013
Safety and Efficacy Study of CEP-10953 in the Treatment of Excessive Sleepiness Associated with Narcolepsy
The primary objective of this study is to determine whether treatment with CEP-10953 is more effective than placebo treatment for patients with excessive sleepiness associated with narcolepsy by measuring mean sleep latency from the Maintenance of Wakefulness (MWT) (20-minute version)(average of 4 naps at 0900, 1100, 1300, and 1500) and…
Neurology
01 Jan 2013
Biological Markers in Parkinson’s Disease
This study will identify abnormalities of a protein called alpha synuclein that is found in the brain of patients with Parkinson’s disease and related disorders to see if it can serve as a disease marker. There is currently no treatment that will cure or delay progression of Parkinson’s disease. Thus,…
Mental Health
01 Jan 2013
Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is not available. Official Title Open Label Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience…
